Alteration of major vault protein in @entity1 @entity463 and its relation with XXXX and @entity983 status.

@entity1 @entity1313 @entity5 @entity470 @entity3173 @entity983 @entity463
@entity463 ( @entity463 ) is the most frequent and @entity1313 . Conventional therapy of surgical removal, radiation and chemotherapy is largely palliative. @entity3173 ( @entity3173 ), the main component of the vault organelle has been associated with multidrug resistance by reducing cellular accumulation of chemotherapeutic agents. With regard to @entity5 , @entity3173 has been shown to be overexpressed in drug resistance development and malignant progression. The aim of the present study was to evaluate the @entity3173 gene dosage levels in 113 archival samples from @entity463 and its correlation with @entity1 ' survival and @entity470 ( @entity470 ) and phosphatase and tensin homolog ( @entity983 ) gene dosages. Fluorescent in situ hybridization revealed polysomy of chromosome 7 in 76.1% of the GBMs and @entity470 amplification in a 64.6% of the @entity5 . Genetic status of @entity470 , @entity983 and @entity3173 copies was determined by multiplex ligation-dependent probe amplification (MLPA) technique. 31% of the @entity5 showed the @entity470 is variant III mutation (EGFRvIII) mutation and 74.3% of them presented amplification of @entity3173 gene. Amplification of @entity470 and @entity3173 was found in a 63.7% and 56.6% of the @entity463 , respectively. An inverse correlation between @entity3173 and @entity983 dosage values was observed. Besides, an inverse relationship between the survival of the @entity1 treated with chemotherapy and the levels of @entity3173 copies was determined. In conclusion, our study reveals an important role of @entity3173 , together with EGFRvIII and @entity983 , in the progression of @entity463 and proposes it as a novel and interesting target for new treatment approaches.
